Athenex Inc. and its partner Almirall SA have achieved the primary endpoint of 100% clearance of actinic keratosis lesions at Day 57 in two Phase III trials of the topical ointment KX2-391. Data details are yet to be unveiled, but based on earlier trial results the drug is thought to be less efficacious than some marketed therapies. Nevertheless, its ease of administration and favorable local skin reaction profile position it well to take market share.
Good Prospects For Athenex/Almirall Following PhIII Actinic Keratosis Results
Two Phase III studies of KX2-391 to treat actinic keratosis of the face and scalp met their primary endpoint of 100% clearance. The treatment could prove more convenient than marketed therapies.
More from Clinical Trials
More from R&D
• By
Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.